Abstract:It remains a big challenge to develop HDAC inhibitors effective for solid tumors. Previous studies have suggested that the feedback activation of JAK-STAT3 pathway represents a key mechanism leading to resistance to HDAC inhibitors in breast cancer, suggesting the therapeutic promise of JAK/HDAC dual inhibitors. In this work, we discovered a series of pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK and HDAC dual inhibitors. Especially, compounds 15d and 15h potently inhibited JAK1/2/3 and HDAC1/6 and displayed antiproliferative and proapoptotic activities in triple-negative breast cancer cell lines. Besides, compounds 15d and 15h also diminished the activation of LIFR-JAK-STAT signaling triggered by tumor-associated fibroblasts, which suggests that these compounds could potentially overcome the drug resistance caused by the tumor microenvironment. More importantly, compound 15d effectively inhibited the tumor growth in MDA-MB-231 xenograft tumor model. Overall, this work provides valuable leads and novel antitumor mechanisms for the treatment of the SAHA-resistant triple-negative breast cancers.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02111?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02111</a>.Supporting tables; 1H NMR, and 13C NMR of all target compounds; HPLC spectra and HRMS of the representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_001.pdf">PDF</a>)Molecular formula stings (CSV) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_002.csv">CSV</a>)Predicted binding mode of 6a in the ATP pocket of JAK2; surface representation of 6a in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_003.pdb">PDB</a>)Predicted binding mode of 15d in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_004.pdb">PDB</a>)Predicted binding mode of 16b in the ATP pocket of JAK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3FUP">3FUP</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_005.pdb">PDB</a>)Predicted binding mode of 6a in the active site of HDAC6; surface representation of 6a in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_006.pdb">PDB</a>)Predicted binding mode of 15d in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_007.pdb">PDB</a>)Predicted binding mode of 16b in the active site of HDAC6 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEI">5EEI</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02111/suppl_file/jm0c02111_si_008.pdb">PDB</a>)This article has not yet been cited by other publications.

Abstract 3217: Discovery of novel inhibitors of the epigenetic regulator Kat6a histone acetyl transferase and characterization of their anti-tumor activity

Abstract PO3-26-04: Discovery of novel inhibitors of the epigenetic regulatory KAT6A histone acetyl transferase and their anti-tumor activity in breast cancer cells

Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer

Abstract 1130: First-in-class KAT6A/KAT6B Inhibitor CTx-648 (PF-9363) Demonstrates Potent Anti-Tumor Activity in ER+ Breast Cancer with KAT6A Dysregulation

Abstract PO2-05-08: ISM5043, a novel, selective KAT6 inhibitor for the treatment of advanced and refractory ER+ breast cancer

Inhibition of lysine acetyltransferase KAT6 in ER + HER2 − metastatic breast cancer: a phase 1 trial

Identification of triazolyl KAT6 inhibitors via a templated fragment approach

New KAT6 Inhibitors Induce Senescence and Arrest Cancer Growth

Abstract 4583: Development of selective HDAC6 inhibitors to improve cancer immunotherapy

First-in-human Phase 1 Dose Escalation Study of the KAT6 Inhibitor PF-07248144 in Patients with Advanced Solid Tumors

A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.

Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy

Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, KAT6A, As Potent Senescence-Inducing Anti-Cancer Agents.

Discovery of Benzoylsulfonohydrazides As Potent Inhibitors of the Histone Acetyltransferase KAT6A.

Discovery and Characterization of BAY-184: A New Potent and Selective Acylsulfonamide-Benzofuran In Vivo -Active KAT6AB Inhibitor

Abstract 1646: IK-930, a paralog-selective TEAD inhibitor for treating YAP/TAZ-TEAD dependent cancers

ERα status of invasive ductal breast carcinoma as a result of regulatory interactions between lysine deacetylases KAT6A and KAT6B

Abstract 4582: HDAC6 inhibition reshapes the epigenome of cancer via P300 stabilization

Discovery of Novel Pyrrolo[2,3- d ]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors

Abstract 1425: Epigenetic modulation synergizes with a novel TCR β chain directed antibody-fusion molecule to suppress checkpoint-refractory tumors irrespective of MHC I status

Abstract 2156: IK-930 is a novel TEAD inhibitor for the treatment of cancers harboring mutations in the Hippo signal transduction pathway